Eficiencia del metimazol en la terapia de hipertiroidismo de graves-basedow: una revisión sistemática.

Abstract

Introduction: Graves' disease has an autoimmune origin that gives rise to the overproduction of thyroid hormones where the most affected are women, the same ones who present risk factors, more than 10% of the world population suffers from it and in Latin America its rate is also low. high, adequate treatment thus allows a better quality of life. Thus, the objective of the research is to determine the efficacy of methimazole in Graves-Basedow disease. Methodology: The study carried out of descriptive origin and retrospectively through a systematic review in repositories of scientific bases such as PUBMED, SCIELO, MESH, SCIENCE DIRECT; in relation to methimazole and Graves' disease. Results: It was possible to obtain scientific articles of which: 6 articles correspond to quartile 1, 5 articles from quartile 2 and 8 articles from quartile 3. Conclusions: Treatment with methimazole has an adherence of 75% above other antithyroid drugs, likewise its life time is 4 to 6 hours, unlike other antithyroid drugs that only last 60 minutes, it is rapidly observed in the gastrointestinal tract, and its adverse effects on the kidneys and liver are minor.